A 28-year-old woman with Crohn's disease (CD) of 8 years' duration presents with a 3-month history of progressive right lower abdominal pain, palpable mass in the right iliac fossa, and weight loss (4 kg). She is afebrile, with normal WBC and CRP. Contrast-enhanced CT abdomen shows a 6 cm stricture in the terminal ileum with proximal bowel dilatation and a small fistula to the adjacent small bowel loop. She is currently on mesalamine monotherapy. What is the most appropriate next step in management?

Explanation

## Clinical Presentation: Structuring Crohn's Disease with Fistulization This patient demonstrates **complicated CD** with: - **Stricturing phenotype:** 6 cm terminal ileal stricture with proximal dilatation (mechanical obstruction risk) - **Fistulizing disease:** small bowel-to-bowel fistula - **Chronicity:** 8-year disease duration with inadequate medical control on mesalamine monotherapy - **Absence of active inflammation:** afebrile, normal WBC, normal CRP (suggests fibrostenosing rather than inflammatory pathology) ## Pathophysiology: Why Medical Therapy Fails in Stricturing Disease **Key Point:** Strictures in CD are primarily **fibrotic** (collagen deposition and smooth muscle hypertrophy), not inflammatory. Biologics and corticosteroids target inflammation and are ineffective for established fibrotic strictures. **High-Yield:** The Montreal Classification divides CD phenotypes: - **Inflammatory (B1):** responsive to medical therapy - **Stricturing (B2):** fibrotic; medical therapy fails - **Penetrating (B3):** fistulizing; requires escalation or surgery This patient has **B2 + B3** (stricturing + fistulizing) disease. ## Decision Algorithm: When to Operate in CD ```mermaid flowchart TD A[Crohn's disease with stricture/fistula]:::outcome --> B{Active inflammation?}:::decision B -->|Yes, mild-moderate| C[Optimize medical therapy: biologics + corticosteroids]:::action B -->|No, fibrotic stricture| D[Assess for obstruction symptoms]:::decision D -->|Recurrent obstruction or fistula| E[Surgical resection]:::urgent D -->|Asymptomatic stricture| F[Observe or consider endoscopic dilation]:::action E --> G[Resect diseased segment + primary anastomosis]:::action C --> H{Response at 8-12 weeks?}:::decision H -->|Yes| I[Continue maintenance]:::action H -->|No| J[Escalate or consider surgery]:::urgent ``` ## Why Surgery Is Indicated Here | Feature | Implication | |---------|-------------| | 6 cm stricture | Likely fibrotic; high risk of obstruction | | Fistula present | Penetrating disease; medical therapy alone insufficient | | Normal inflammatory markers | Suggests fibrosis, not active inflammation | | Inadequate response to mesalamine | 8 years on monotherapy = failed medical control | | Palpable mass + symptoms | Symptomatic disease requiring intervention | **Clinical Pearl:** Surgery is **not contraindicated** in CD and is often necessary for: - Symptomatic strictures with obstruction - Fistulizing disease unresponsive to medical therapy - Perforation or abscess - Dysplasia or malignancy Resection of the diseased terminal ileum with primary ileocolic anastomosis is the standard approach. ## Why Other Options Fail **Option A (Escalate mesalamine + budesonide):** - Budesonide is for inflammatory flares, not fibrotic strictures - Will not reverse established fibrosis or resolve fistula - Delays necessary surgical intervention **Option B (Infliximab induction):** - Biologics are most effective for **inflammatory** CD - Fibrotic strictures do not respond to TNF-α inhibitors - Fistulas may respond to infliximab, but the stricture will persist - Patient already has 8 years of disease with inadequate control — escalation is unlikely to succeed **Option D (Endoscopic dilation):** - Stricture is 6 cm long (too long for safe dilation) - Fistula present increases perforation risk during dilation - Temporary measure only; recurrence is high in CD - Not appropriate as primary therapy for symptomatic stricturing disease [cite:Harrison 21e Ch 295; Robbins 10e Ch 17]